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HUMAN CLINICAL ARTICLE
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Abstract
Mesenchymal stem cells (MSCs) have natural immunoregulatory functions that have
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been explored for medicinal use as a cell therapy with limited success. A phase Ib
study was conducted to evaluate the safety and immunoregulatory mechanism of
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action of MSCs using a novel ex vivo product (SBI-101) to preserve cell activity in
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secreted factor activity that was associated with anti-inflammatory signatures in the
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patients with severe acute kidney injury. Pharmacological data demonstrated MSCmolecular and cellular profiling of patient blood. Systems biology analysis captured
multicompartment effects consistent with immune reprogramming and kidney tissue
repair. Although the study was not powered for clinical efficacy, these results are
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supportive of the therapeutic hypothesis, namely, that treatment with SBI-101 elicits
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tissue injury to tissue repair. Ex vivo administration of MSCs, with increased power
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an immunotherapeutic response that triggers an accelerated phenotypic switch from
of testing, is a potential new biological delivery paradigm that assures sustained MSC
activity and immunomodulation.
KEYWORDS
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monocyte, MSCs
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• MSC-secreted factors are detectable after manufacturing, shipping, and product use as a

• Ex vivo mesenchymal stem cell (MSC) therapy is feasible without any signs of significant
safety concerns.
powerful demonstration of a viable cell product.
• MSCs respond in a patient-specific manner as a new paradigm in precision immunotherapy.
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© 2021 Sentien Biotechnologies Inc. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals LLC on behalf of AlphaMed Press.
STEM CELLS Transl Med. 2021;1–14.

wileyonlinelibrary.com/journal/sct3

1

2

SWAMINATHAN ET AL.

Funding information
National Institutes of Health National Institute
of Diabetes and Digestive and Kidney
Diseases, Grant/Award Number:
5R44DK085766

• A systems biological pharmacodynamic response was observed at multiple physiological
levels and included systemic signs of cytokine switching, peripheral immune cell dynamic
changes, and local kidney injury marker reductions.
• A stratification approach that clustered biological families of biomarkers together demonstrated statistically relevant responses to ex vivo MSC therapy.

Significance statement
Conventional administration of mesenchymal stem cells (MSCs) by intravascular routes has
shown low persistence of cells, potentially shortening their therapeutic window. In the cell therapy product described here, SBI-101, MSCs are immobilized in an ex vivo drug delivery device
that circulates the patient's blood akin to a dialysis procedure. Use of this ex vivo cell therapeutic device controls, for first time, the exposure of a patient to MSCs and their
immunomodulating secreted factors. Data from this phase I/II trial support the therapeutic
hypothesis that ex vivo delivery of MSC-secreted factors leads to immunomodulation, reprogramming of immune cells, and subsequent protection of kidney injury.
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I N T RO DU CT I O N

promote T helper cell type 1 (Th1)/type 2 (Th2) switching, and polarize
monocytes/macrophages toward a regulatory M2 phenotype.28 After

Dysregulated, immune-mediated inflammation is a core component of

decades of MSC research, an allogeneic MSC product finally received

many conditions that include acute kidney injury (AKI), burn injury,

marketing approval in 2018 for the local treatment of complex perianal

acute respiratory distress syndrome, acute liver failure, sepsis, and coro-

fistulas in Crohn's disease.29 More recently, systemic administration of

1-8

navirus disease 2019 (COVID-19).

All these conditions have been

allogeneic MSC treatment in pediatric patients with acute graft vs host

associated with high morbidity and mortality rates.9,10 A concert of

disease showed a significant improvement in survival rate compared

cytokines and components of the innate immune system are the initial

with historical controls and a sustained therapeutic effect at 6 months

11-14

Under normal circumstances, these

after treatment (NCT02336230), although no therapeutic biomarkers

mediators neutralize the original insult and, with a subsequent adaptive

were clearly associated with the response.30 In addition, the potential

mediators of inflammation.

15-17

immune response, restore homeostasis.

In critical illnesses, these

applicability of these cells to treat sequalae of COVID-19 infection has

innate mediators of inflammation may become dysregulated, driving a

introduced a new indication for MSCs in systemic immunoregula-

“cytokine storm” and eliciting an abnormal adaptive immune response

tion.31-33 Nonetheless, conventional administration of MSCs by intra-

18-21

that augments and propagates inflammation systemically.

A second

vascular routes has shown low persistence of cells and may have the

phase of acute inflammation, mediated primarily by tissue stromal and

potential to induce clotting events.34 These pharmacological barriers

immune cells, is triggered by the initial inflammatory response and can

manifested by a short and uncontrolled exposure of a patient's blood to

last for days to weeks. After initial activation of neutrophils and mono-

MSCs and their secreted factors have likely contributed to the lack of

cytes, a second wave of intraparenchymal infiltration by adaptive

efficacy in several clinical studies with the intravascular administration

immune cells, such as effector memory T cells, mitigates further tissue

of MSCs.34-37

destruction and ideally begins a tissue remodeling process and acceler-

To control viability and exposure to MSCs and their secreted fac-

ates tissue repair. These infiltrating cells are primed by systemic factors

tors, while simultaneously reducing safety risks of thromboembolic

before encountering a local tissue microenvironment containing acti-

events and pulmonary injury due to systemic infusion, SBI-101 was

vated macrophages and tissue cytokines. The acute inflammatory

developed as an ex vivo MSC product that immobilizes allogenic bone

response also incorporates counterregulatory components, such as rec-

marrow-derived MSCs, at a target cell number, on the extracapillary

ruited regulatory T cells and induced anti-inflammatory cytokines (eg,

space of a hollow fiber hemofiltration device. Circulating blood cells

interleukin [IL]-10).22-24 These mediators are key regulators in the phe-

passing through the hollow fibers are exposed to MSC-secreted factors

notypic switch from tissue injury to tissue repair. Thus, rebalancing this

through a high pore size plasmapheresis membrane (Figure 1A). This

multifocal inflammatory response may be a potential approach to

configuration enables controlled, extended exposure of the full MSC

restoring underlying organ function after severe injury.

dose and facilitates cross-membrane, bidirectional communication

Mesenchymal stem cells (MSCs) secrete several types of molecules

between the MSCs and the patient's blood circulating in the intra-

(eg, lipids, cytokines, chemokines, and exosomes) that collectively mod-

capillary space of the filter. SBI-101 recapitulates the in vivo three-

ulate an immune cell response to inflammation.25-27 Through a multi-

dimensional microenvironment of MSCs, that is, pericytes in capillary

tude of in vitro and animal studies, they have been shown to module

vessels.38 SBI-101 is designed to operate in the context of extracorpo-

just about every circulating immune cell but are well characterized for

real therapy and can be used in tandem with other ex vivo devices such

their ability to inhibit T-cell activation, induce regulatory T cells,

as renal replacement therapy (RRT) used in AKI (Figure 1B).

3
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Comprehensive preclinical testing of SBI-101 in vitro39,40 and in

double-blind, sham-controlled, multiple ascending dose, parallel-group

animal models of disease41-43 has shown that the product is safe and

study investigating the safety, tolerability, and pharmacology of SBI-

efficacious in various models of systemic inflammatory disease. We

101 in adult subjects with AKI-D while on CRRT. The design of the

hypothesized that MSC immunoregulation via SBI-101 may be of

study is shown in Figure 1C. Sixteen subjects were meant to be ran-

therapeutic value in dialysis-dependent AKI (AKI-D), wherein initial

domized, in a 2:1 ratio, to an active low dose of SBI-101 (250  106

kidney parenchymal cell loss is exacerbated by a local and systemic

MSCs) or to a sham (no MSCs). However, the study randomized

inflammatory response. To evaluate this hypothesis, a phase I/II, mul-

12 patients to active treatment and four to sham treatment because

ticenter, randomized, sham-controlled, double-blind study of SBI-101

the protocol allowed replacement of subjects to the same treatment

in subjects with AKI receiving continuous renal replacement therapy

allocation who do not complete a minimum of 12 hours of treatment.

(CRRT) was initiated, and an interim analysis of the group receiving an

Use of a sham device reduces bias in interpreting data, particularly dur-

active dose (250  10 cells per SBI-101) was compared with the

ing evaluation of safety parameters possibly related to the study drug.

sham-treated group (NCT03015623).

The study captured general and specialized safety assessments and

6

pharmacological parameters in plasma and urine.
The study population to be treated in this study included those

2

MATERIALS AND METHODS

|

who had been diagnosed with AKI of any etiology not specifically
excluded in the exclusion criteria and had been, in the Investigator's

2.1

|

Study design

opinion, stable for at least 12 hours after commencement of CRRT
and were likely to require CRRT for an additional 48 hours. Complete

This study (SBI-101-01, NCT 03015623, IND 17204) was designed as a

inclusion and exclusion criteria have been previously described.44 All

multicenter (conducted in 12 centers in the United States), randomized,

subjects or legally acceptable representatives provided written

F I G U R E 1 Schematic illustration of SBI-101-01. A, Schematic of cell membrane interaction with blood flow. B, Extracorporeal circuit with
integrated SBI-101. The configuration enables in situ monitoring via extracapillary sampling. C, Study design. D, Sampling for exploratory endpoint
analysis. AE, adverse event; AKI, acute kidney injury; AKI-D, dialysis-dependent acute kidney injury; CRRT, continuous renal replacement therapy;
MSC, mesenchymal stem cell; MWCO, molecular weight cutoff; PD, pharmacodynamic; PK, pharmacokinetic; SAE, serious adverse event; T, time

4
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informed consent. The study population for analysis included the

investigational therapy, during CRRT/Investigational therapy, on

Safety Analysis Set, which consisted of all subjects who signed the

CRRT/off investigational therapy, off CRRT/investigational therapy)

informed consent and were exposed to the investigational agent.

and by group and treatment group. Sample collection was performed
at clinical sites as previously described.44

2.2

|

Investigational agent and its administration

The investigational agent was SBI-101. Allogeneic MSCs are the

2.4 | Assessment of efficacy and exploratory
endpoints

active ingredient (drug substance) in SBI-101 (Figure 1A). The MSCs
are derived from the bone marrow of a healthy donor and processed

All analyses of efficacy and exploratory endpoints were performed on

into a master cell bank and working cell banks, in compliance with

the Per Protocol Set. Two additional sham-treated subjects whose

Good Manufacturing Practice standards for biologics and cellular ther-

treatments ran for 10.5 and 3 hours were also included since this

apies. SBI-101 (drug product) is a combination of the allogeneic cells

short time of perfusion with the empty filter should not affect efficacy

and a Food and Drug Administration-approved hollow fiber plasma

and pharmacological analysis. Hence, four patients were considered in

separator. Cells are immobilized onto the extracapillary surface of the

each group.

polyethylene hollow fibers. The hollow fibers are contained within a
transparent housing.

Samples were collected as shown in Figure 1C. Sample testing
using a multiplex immunoassay method for proteins detected in the

The sham is the hollow fiber plasma separator but devoid of cells.

extracapillary compartment of the product or in-patient plasma sam-

SBI-101 was administered in sequence with a NxStage System

ples were collected in a plasma preparation tube (362 788; BD Biosci-

One (NxStage Medical Inc., Lawrence, Massachusetts) or Baxter Pris-

ences, San Jose, California) performed at Eve Technologies (Calgary,

maflex system (Baxter, Deerfield, Illinois), each configured for CRRT

Canada) (Table S3). Flow cytometry testing of patient leukocytes was

(Figure 1B). To be part of the per protocol analysis set, subjects must

performed by ReachBio (Spokane, Washington). Blood was collected

have remained on SBI-101 therapy or sham for at least 12 and up to

in CPT tubes (362 753; BD Biosciences), and peripheral blood mono-

24 hours (exclusive of rinse-back procedures). Subjects receiving less

nuclear cells (PBMCs) were isolated and cryopreserved at a concen-

than 12 hours of treatment may have been replaced. All subjects

tration of 2 million per milliliter. Six panels were used for each sample

exposed to SBI-101 or sham were evaluated in the Treated

(Table S4).

Analysis Set.
SBI-101 was integrated with the NxStage System One or Baxter
Prismaflex system immediately after priming the NxStage System One

2.5

|

Analysis

circuit or Baxter Prismaflex circuit and before removing air bubbles
from the lines. At the end of treatment, the subject's blood was ret-

SBI-101 (active) dose groups were compared against the sham group

urned prior to the subject's removal from the CRRT circuit.

using unpaired, nonparametric analyses for data not normally distributed, a Wilcoxon rank sum test for ordinal outcomes, and Fisher's
exact test for binary outcomes. Within-dose comparisons (using the

2.3

|

Assessments of safety

subject as his or her own control) were evaluated using a paired t test
for continuous endpoints and using McNemar's paired comparison

All safety analyses were performed on the Safety Analysis Set. Sub-

test for changes from baseline for binary outcomes. An exact binomial

jects who were randomized but did not receive SB-101 were consid-

test was used to compare overall rates for safety, tolerability, and

ered screen failures. Study populations for analysis included the

28-day survival outcomes relative to a predetermined acceptability

following: (a) Safety Analysis Set: The Safety Analysis Set consisted of

standard. All statistical tests were two-sided with a .05 significance

all subjects who signed the informed consent and were exposed to

level.

SB-101. All safety analyses were performed on the Safety Analysis
Set. Subjects who were randomized but did not receive SB-101 were
considered screen failures. (b) Treated Analysis Set: The Treated Anal-

3
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|

ysis Set consisted of all subjects who received SB-101 or sham control, whether or not they completed the full 12 hours of treatment. All

3.1

|

Demographics and safety

analyses of efficacy and exploratory endpoints were performed on
the Treated Analysis Set. (c) Per Protocol Set: The Per Protocol Set

A total of 16 subjects were enrolled in the study: 12 in the SBI-101

consisted of all subjects who received SB-101 for a minimum of

active (250  106 MSCs) group and 4 in the sham group (study design

12 hours and had no important protocol deviations. The safety and

is depicted in Figure 1C; other information such as inclusion and

tolerability measurements included adverse events, physical examina-

exclusion criteria has been previously described44). The primary cause

tion findings, vital signs, electrocardiograms, and laboratory tests.

of AKI-D in 13 of the 16 subjects enrolled was ischemia reperfusion

Results were presented separately by treatment phase (pre-CRRT/

injury (10 active and 3 sham). In the remaining three subjects, sepsis

5
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was the cause of AKI-D (two active and one sham). Among the 13 sub-

SBI-101 containing 250  106 MSCs, indicating that cells are active

jects with ischemia reperfusion injury, nine subjects had major surgery

and secreting proteins between the time they are seeded in SBI-101

(cardiac, vascular, abdominal) leading to AKI-D (six active and three

and when SBI-101 is integrated to the patient. Not surprisingly, all

sham). The demographics of subjects in the study were well balanced

these factors have been previously described as present in the MSC

for age, gender, and body mass index within the constraints of the

secretome.25,46,47 All factors were then compared with viability at

numbers of subjects in each group (Table S1).

inoculation to investigate the potential correlation of cell viability and

The Per Protocol Set included six subjects (four active and two

analyte levels at product baseline. High correlations were found

sham) who received SBI-101 for a minimum of 12 hours and had no

between viability and levels of MCP-1 (CCL2), TGF-β1, and VEGF-A

significant protocol deviations. The remaining 10 participants, 8 of

(Figure 2B). All together, these results provide important insights into

12 (67%) in the active group and 2 of 4 (50%) in the sham group, were

the quality and consistency of SBI-101 manufacturing and establish a

each disconnected from SBI-101 treatment prior to 12 hours of treat-

baseline for characterizing the response of MSCs to patient-specific

ment, although all continued with RRT as per standard of care. Most

inflammatory profiles.

SBI-101 discontinuations were due to circuit clotting. Although not
uncommon in clinical practice,28 the frequency of circuit clotting in
this study significantly limited the number of subjects evaluable for
treatment effects. The protocol did not require anticoagulation, but

3.3 | PK observations of patient-specific MSC
activity

principal investigators had the option to administer anticoagulation if
clinically indicated. Notably, the four Per Protocol Set subjects in the

Pharmacokinetics is typically known as the study of the bodily absorp-

active arm all received anticoagulation during treatment and success-

tion, distribution, metabolism, and excretion of a drug, simplistically

fully completed the full 24 hours of treatment.

described as “what the body does to the drug.” Assessment of pharma-

There were no serious and unexpected suspected adverse reactions

cokinetics in cellular therapies is problematic because the “drug,” (ie,

or unanticipated adverse device effects reported during the study. The

MSCs) cannot be retrieved and assayed after infusion. In SBI-101,

mortality rate was consistent with what has been reported in the litera-

MSCs are immobilized in an extracorporeal cartridge so that the drug is

ture for AKI.45 No deaths or serious adverse event were considered

in a concentrated location that can be assayed and even retrieved after

related to the investigational agent as determined by the principal investi-

patient use. Sampling the extracapillary space in SBI-101 allows for

gators, the Safety Committee, and the Data Safety Monitoring Board.

direct measurement of plasma ultrafiltrate during treatment and hence

Patient deaths were attributed to baseline conditions or complications

offers a unique way of interrogating how the body is affecting the drug.

experienced during their hospital stay, not unexpected in a critically ill

Measurements of MSC activity from within SBI-101 assessed during

population with significant comorbidities. Based on the data available to

treatment (30 minutes, 6 hours, 12 hours, 18 hours, and 24 hours). Sev-

date, no overt safety signals have been identified. Pharmacokinetic

eral MSC-secreted markers increased over time compared with sham

(PK) and pharmacodynamic (PD) analyses was performed on subjects in

(Figure 3A). MSCs within SBI-101 were secreting proteins in a dynamic

the Per Protocol Set who were treated with low-dose SBI-101 for

fashion, including IL-6, IL-8, MCP-3 (CCL7), and epithelial-derived

24 hours (n = 4) or sham-treated subjects (n = 4). Table S1 summarizes

neutrophil-interacting protein 78 (CXCL5). Given the measurement of

subjects and their treatment allocations, including exposure time to SBI-

human MSC factors in a background of human patient plasma, the

101 and baseline measurements of inflammation and kidney failure.

source of these proteins cannot be definitively established. However,
the delta between active SBI-101 therapy and sham devices as a negative control provides confidence that these factors were likely produced

3.2 | Confirmation of SBI-101 bioactivity prior to
treatment

by MSCs. Importantly, factors enriched in the EC space during treatment did not necessarily equate to increased plasma levels of such factors. This is well illustrated by IL-6, a factor that clearly increased inside

SBI-101 uniquely allows for sampling to assure the activity and con-

SBI-101 during treatment, whereas participant plasma levels were

sistency of the cell therapy product by indirectly measuring cell-

decreased after treatment (Figure S1). These results suggest that SBI-

specific factors. A sample from the extracapillary (EC) space was taken

101 creates a local, concentrated environment of MSC-secreted factors

just prior to participant integration and was multiplexed to evaluate if

that are exposed to circulating immune cells within the device, much

MSC-secreted function was still intact after product manufacturing

like an artificial tissue environment.

and distribution to sites. Analytes with significant differences between

Each biomarker collected from the EC space of SBI-101 during

active SBI-101 (n = 11) and sham (n = 3) are shown in Figure 2A.

the study was quantified using traditional pharmacokinetic methods

Fractalkine, platelet-derived growth factor AA (PDGF-AA), trans-

to identify a maximum concentration (Cmax) or the time-weighted

forming growth factor (TGF)-β1, fibroblast growth factor 2 (FGF-2),

average (TWA). Because it was hypothesized that SBI-101 had the

growth-regulated oncogene (GRO) alpha (C-X-C motif chemokine

potential for modulating multiple biological pathways, these two met-

ligand [CXCL] 1), IL-6, IL-7, IL-8, monocyte chemoattractant protein

rics were chosen to provide an enhanced understanding of changes in

(MCP)-1 (C-C motif chemokine ligand [CCL] 2), vascular endothelial

potential biomarkers. Cmax represented a maximum concentration of

growth factor A (VEGF-A), and TGF-β2 were all found to be present in

biomarker observed over the complete dosing interval. TWA24

6
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F I G U R E 2 Mesenchymal stem cell (MSC) factors measured in the extracapillary space of SBI-101 prior to initiation of therapy. A,
Extracapillary samples collected from SBI-101 prior to patient therapy displayed significant increased levels of cytokine and growth factor
secretion in the low-dose (250  106 MSCs) SBI-101 (n = 11) compared with sham (n = 3). Fractalkine, TGF-β1 (*P < .05), FGF-2, GRO alpha
(C-X-C motif chemokine ligand 1), IL-6, IL-7, IL-8, MCP-1 (C-C motif chemokine ligand 2 [CCL2]), VEGF-A, and TGF-β2 (**P < .01) were detected
in the seeded SBI-101 devices. B, Correlation of MSC viability at seeding of SBI-101 to that of MCP-1 (CCL2), TGF-β1, and VEGF-A were high
with calculated R2 values of 0.68, 0.64, and 0.63, respectively. Data are presented as scatter plots with means ± SD. Nonparametric MannWhitney unpaired test was used for statistical analysis (*P < .05; **P < .01). 250M, 250  106 MSCs; FGF-2, fibroblast growth factor 2; GRO
alpha, growth-regulated oncogene alpha; IL, interleukin; MCP-1, monocyte chemoattractant protein 1; TGF, transforming growth factor;
VEGF-A, vascular endothelial growth factor A

provided an average concentration of a given biomarker in SBI-101

groups. This finding could be due to small sample sizes and truncated

over a 24-hour treatment period.

sampling schemes rather than physiological phenomena. Given that

Effect sizes and Z-scores were used to characterize differences

TWAs carry information from repeated within participant samples,

between active and sham groups for each PK biomarker. Biomarkers

whereas Cmax is obtained from a single measure and is highly

were identified as “contenders” (i.e., of potential relevance) if the

influenced by sample collection time, preferential focus was placed on

effect size was shown to be greater than one for both Cmax and TWA.

TWA. The TWA24 for each of the factors listed above was analyzed

The top contenders with the highest effect sizes for pharmacokinetics

in a heatmap showing TWA24 values for each patient (Figure 3C). A

are shown in Figure 3B. Not surprisingly, these were factors typically

heatmap was also created with baseline plasma levels for creatinine,

associated with the MSC secretome: granulocyte colony-stimulating

blood urea nitrogen, C-reactive protein, tumor necrosis factor α

factor (G-CSF), soluble vascular endothelial growth factor receptor

(TNFα), and interferon γ (IFNγ) for each participant. Put together, each

1 (sVEGFR1), IL-8, IL-9, IL-6, TGF-β1, IL-7, and TGF-β2. Of note, nei-

participant background was unique with differing levels of disease

ther metric of exposure (TWA24 and Cmax) appeared to be substan-

and inflammation. Separately, the MSC response also showed a

tially more sensitive to differences between the active and sham

unique profile for each participant, suggestive of a “personalized”

7
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F I G U R E 3 Pharmacokinetic analysis of SBI-101 treatment shows sustained and subject-specific exposure to mesenchymal stem cell (MSC)–
secreted factors (n = 4 per group). A, Multiplex immunoassay measurements of MSC-secreted factors in SBI-101 (blue) compared with sham
(black). B, PK biomarkers with effect sizes greater than one (absolute value). C, Participant-specific analysis of MSC-secreted factors as a function
of patient baseline phenotype. A heatmap was created using measurements of baseline inflammatory and kidney function markers (red) and
TWA24 for the secreted factors during therapy (blue). Comparative analysis of intensities was calculated within each row with darker colors
representing larger values. D, Standardized TWA24 Z-scores in treated and sham subjects for PK composite: G-CSF, IL-6, IL-7, IL-8, IL-9,
sVEGFR1. Differences between sham and treated subjects can be easily detected as the full range of Z-scores observed among treated patients
was positive. 250M, 250  106 MSCs; BUN, blood urea nitrogen; CRP, C-reactive protein; EC, extracapillary; ENA 78, epithelial-derived
neutrophil-interacting protein 78; G-CSF, granulocyte colony-stimulating factor; IFNγ, interferon γ; IL, interleukin; MCP-3, monocyte
chemoattractant protein 3; PK, pharmacokinetic; sCmax, maximum concentration; sVEGFR1, soluble vascular endothelial growth factor receptor 1;
TGF, transforming growth factor; TNFα, tumor necrosis factor α; TWA24, time-weighted average over 24-hour treatment period
therapy. Overall, these results suggest that SBI-101 therapy is work-

data strongly support SBI-101 as a combinatorial biological delivery

ing as hypothesized, where (a) known MSC factors are being secreted

system, controlling

continuously in SBI-101 and (b) MSCs are dynamically responsive to

chemokines in a local systemic blood compartment.

the exposure of

multiple cytokines

and

participant-specific inflammatory signals. In addition, PK analysis also
verified a panel of factors that were increased in active SBI-101 treatment, which can be followed in future clinical studies. Indeed, a putative composite PK endpoint comprising G-CSF, IL-6, IL-7, IL-8, IL-9,

3.4 | PD multicytokine modulation after MSC
therapy

and sVEGFR1 was identified, showing a clear separation between
TWA24 in the active vs sham groups (Figure 3D), which could be used

Molecular and cellular biomarkers were tested as exploratory end-

in subsequent studies to further understand PK/PD relations. These

points to study the PD changes associated with SBI-101 treatment.

8
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Peripheral blood sampling was performed during screen A, screen B,

Known pro-inflammatory markers such as TNFα and IFNγ remained

predose baseline, and post-treatment days 1, 3, 7, 14, 21, and 28. The

low or decreased in the active group, whereas corresponding values in

start of PD exposure was defined as 24 hours after initiation of treat-

the sham group continued to increase (Figure 4A). For known anti-

ment. PD areas under the curve (AUCs) characterized the total change

inflammatory markers IL-10 and TGF-β1, the reciprocal response

in exposure at discrete intervals, starting with day 1, and were

occurred, suggesting that the presence of SBI-101 has an inflammatory

increased incrementally up until the end of sample collection on day 28.

mediating response (Figure 4B). Concordantly, the ratio of IL-10 to TNFα

PD TWAs represented the TWA change in concentration over the same

showed a high effect size that was above one in every assessment

collection intervals. Differences between TWAs and AUCs were not

through day 7 (Table S2). All these changes are consistent with MSC biol-

substantive; however, TWAs allowed pooling of endpoints that may

ogy.48-50 Decrease in TNFα levels at day 3 after treatment inversely cor-

have had different collection periods and were therefore used preferen-

related with time to treatment (Figure S2), suggesting that treating

tially over AUCs. Although assessments continued beyond 7 days of

patients earlier in their injury may show stronger PD effects and ulti-

treatment, the most dynamic period occurred in the immediate week

mately better therapeutic efficacy. Overall, molecular biomarker analysis

following treatment; although AUCs and TWAs were generated that

was consistent with the therapeutic hypothesis and MSC mechanism of

represented greater periods of time, the earlier assessments were there-

action. Trends appeared to be somewhat transient, and further analysis

fore considered most relevant with regard to detecting PD effects. As

with higher doses and with increased number of subjects after day 7 after

before, effect sizes and Z-scores were used to characterize differences

treatment will be needed to further evaluate the duration of PD effect.

between active and sham groups for each PD biomarker. Absolute

To examine these exploratory data from a systems biology perspec-

values of effect sizes were generated for each biomarker. A biomarker

tive, pathway analysis was performed on the analyte data collected

was considered a contender if the absolute value for the effect size was

from the plasma of subjects in both groups. Analytes at day 3 were nor-

greater than or equal to one for both ratios of log-transformed values

malized to predose baseline levels and entered into the Ingenuity Path-

over baseline and TWA. A list of “top contender” PD cellular and molec-

way Analysis software. The comparison analysis for subjects with active

ular biomarkers is shown in Table S2.

SBI-101 treatment (observations 1-4) vs sham treatment (observations

F I G U R E 4 Pharmacodynamic effects in plasma of patients after treatment with SBI-101. Plasma measurements of, A, pro-inflammatory
markers TNFα and IFNγ and, B, anti-inflammatory markers IL-10, TGF-β1 in treated (blue) and sham patients (black). Values represent the mean at
each time point of the change from baseline (predose values or screen B in the case predose was not available) for each biomarker ± SEM (n = 4
per group). C, Unsupervised pathway analysis of patient response at day 3 normalized to baseline. Disease and function analysis comparison
heatmap was sorted by hierarchical clustering based on sample activation score. The activation score (Z-score) predicts direction of potential
regulators assessing the match of observed and predicted upstream or downstream processes. Z-score serves as both a significance measure and
a predictor for the activation state of the regulator (orange, +/activation, blue, /inhibition). IFNγ, interferon γ; IL-10, interleukin-10; TGF,
transforming growth factor; TNFα, tumor necrosis factor α; Tx, treatment
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F I G U R E 5 SBI-101 effect on circulating monocytes. A, Flow cytometric analysis of different monocyte populations in patient peripheral
blood mononuclear cells after treatment with SBI-101 (blue) or sham (black). B, Quantification of monocyte chemoattractants MCP-1 (C-C motif
chemokine ligand [CCL] 2), MCP-2 (CCL8), and MCP-3 (CCL7). Results are represented as TWAs ± SEM (n = 4 per group). MCP, monocyte
chemoattractant protein; TWA, time-weighted average

5-8) was performed using high stringency conditions (using cutoff

1.2

in different populations and subsets (Table S2), with robust changes at

[down] and +1.2 [up]) and based on trend and Z-score, and a resulting

the level of monocytes. Preclinical testing of SBI-101 in animal models

heatmap was generated (Figure 4C). Results showed a distinct cluster-

suggested that monocytes might be decreased with treatment, consistent

ing of SBI-101-treated compared with sham-treated subjects. SBI-

with findings from other groups.51 Here, quantification of each monocyte

101-treated subject profiles suggested broad spectrum inhibition of

subpopulation following clinical application of SBI-101 suggests that this

immune-mediated pathways (blue), whereas sham-treated subjects

finding is also consistent in humans. Both classic and intermediate

showed most of those same pathways as activated (orange). This unbi-

populations decreased, whereas the nonclassic population did not change

ased analysis supports the notion that SBI-101 is modulating the

(Figure 5A). This decrease in monocyte populations manifested in a phar-

immune system broadly, a key feature of cell therapy that is distinct

macodynamic response with known decreases in monocyte chemo-

from single-factor agents. Intriguingly, one subject profile in the sham

attractants MCP-1 (CCL2), MCP-2 (CCL8), and MCP-3 (CCL7) over time

group (patient 5 in Figure 4B) resembled the SBI-101-treated subjects

and with greater effect than in the sham group (Figure 5B). These results

more so than the other sham-treated subjects. After unblinding the

were also consistent with pathway analysis focused on monocyte-related

study, we learned that this subject presented with septic shock that,

diseases showing inhibition with low-dose SBI-101 treatment monocyte-

during the treatment period, was in a resolving phase. Anecdotally, this

related pathways (Figure S3). Specific subsets of B cells (unswitched

control group subject thus provided the profile of a patient with AKI

memory and marginal zone) were found to be increased after treatment,

with naturally resolving systemic inflammation from sepsis. This profile

and other trends in T-cell, natural killer cell, and dendritic cell subsets

was similar to those treated with SBI-101, supporting the hypothesis

were also noted (Table S2). These preliminary findings will need to be fur-

that SBI-101, through broad immunomodulation, is resolving inflamma-

ther validated with larger sample size and supporting blood differential

tion and accelerating healing and tissue repair.

test results.

3.5 | Peripheral immune cell dynamics and
associated chemokines are altered after MSC therapy

3.6 | Stratification of SBI-101 responses based on
composite endpoints reveals multifocal therapy

In addition to measuring molecular biomarkers, PBMCs from each subject

A systems biology view of molecular and cellular PD biomarkers with

were collected for immunophenotypic analysis. Changes were observed

high effect sizes illustrates a therapy that affects both the adaptative
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F I G U R E 6 Effect sizes of individual and composite pharmacodynamic markers. A, SBI-101 induced changes in both molecular and cellular
parameters with effect sizes greater than one. B, Composite groupings were created based on both the magnitude of effect size and the scientific
plausibility of each combination. C, Composite scores were generated for each subject. Composite Z-scores were the average Z-score across
markers within a composite group, for each subject and time point. Composite endpoints were generated for each treatment group by averaging
the individual composite Z-scores in each group. Finally, composite endpoints were used to generate composite effect sizes, calculated as the
difference between treated and control composite endpoints divided by the pooled SD. D, Values of P from a two-tailed t test performed for
each group at each observation day after treatment. G-CSF, granulocyte colony-stimulating factor; I-309, inflammatory cytokine I-309; IFNγ,
interferon γ; IL, interleukin; KIM-1, kidney injury molecule 1; MCP, monocyte chemoattractant protein; PD, pharmacodynamic; sTNFR, soluble
TNF receptor; TGF, transforming growth factor; Th1, T helper cell type 1; Th2, T helper cell type 2; TNF, tumor necrosis factor; TRAIL, TNFrelated apoptosis-inducing ligand; TWA, time-weighted average
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and innate immune system, increasing Th2 anti-inflammatory markers

inflammatory processes. Inflammation is an important contributor to

(eg, IL-10, TNFα, IL-13) while decreasing pro-inflammatory or Th1

mortality and resistance to treatment among patients with AKI.2,3,54

cytokines (IFNγ, TNF-related apoptosis-inducing ligand [TRAIL], and

In AKI-D, as in many other critical injuries, no single disease-targeted

TNFα) (Figure 6A). Importantly, certain kidney injury markers (kidney

therapy exists. Here we describe preliminary data from our phase I/II

injury molecule 1 [KIM-1] and osteoactivin) were also found to be

study in AKI-D where we tested a novel cell therapy product designed

decreased with an effect size greater than one. In order to enhance

to regulate systemic inflammation and promote organ repair.

the detectability of effect sizes, pooling of PD endpoints into compos-

The therapeutic hypothesis of SBI-101 is that broad repro-

ite endpoints was also performed. Although PD composites were

gramming of an immune response associated with systemic inflamma-

enhanced via purely mathematical approaches, the most robust effect

tion restores homeostasis and accelerates tissue repair, leading to a

sizes were observed when composites were created based on biologi-

beneficial clinical outcome. SBI-101 is designed to behave as a self-

cal validity (Figure 6B). The effect sizes over time of all six PD group-

sensing and regulating “drug” delivery product where the pharmaco-

ings are plotted in Figure 6C. Pooling PD biomarkers to form

logical load consists of a complex secretome of cytokines and related

aggregate endpoints increased the observed effect sizes for differ-

molecules. Sampling directly from an ex vivo MSC compartment prior

ences between the active and sham groups. Two groups, the mono-

to the patient's connection enabled the first characterization of a

cyte/macrophage group and the “high effect size” group, had effect

complex MSC secretome in humans, which consisted of molecules

sizes greater than four for the first 3 days after treatment, indicating

such as fractalkine, PDGF-AA, TGF-β1, FGF-2, GRO alpha (CXCL1),

that the onset of effect was rapid and highly detectable. Moreover,

IL-6, IL-7, IL-8, MCP-1 (CCL2), VEGF-A, and TGF-β2. Further analysis

the differentiation from sham was sustained in both PD groupings for

of these types of samples, for example, at the level of extracellular

the full 28 days following treatment.

vesicles (EVs), will continue to contribute to product consistency and

Although the largest effect sizes were observed within the first

product characterization. Using a miniaturized version of SBI-101

7 days following the end of treatment, the P values for each composite

ex vivo, MSC-derived EVs have been shown to be altered in size in

endpoint (Figure 6D) showed some significant differences between the

the presence of inflammatory stimuli.40 The same study showed that

active and sham groups up to day 28. In fact, P values for the mono-

MSCs in the bioreactor modified PBMC-secreted factor milieu both

cyte/macrophage group were significant between active and sham at

directly through cell-secreted factors and indirectly via altered EV

every time point measured. The “high effect size group” that comprises

characteristics. The role of EVs in the mechanism of action of ex vivo

a mixture of B-cell subsets, monocytes, G-CSF, IL-10: TNFα, MCP-2

MSC therapy requires further studies.

(CCL8), and TGF-β2 also showed statistical significance up to day 21. A

The study enrolled subjects with severe and life-threatening med-

composite based on the TNFα family members (soluble TNF receptors I

ical conditions. A substantial adverse event profile was expected for

and II, TNFα, and TRAIL) decreased significantly in active subjects on

such a critically ill population with significant comorbidities. No seri-

day 0 (end of 24 hours of treatment), day 3, and day 7, supporting the

ous adverse events were considered related to SBI-101, but a sub-

therapeutic hypothesis that SBI-101 therapy reduces TNFα levels in the

stantial number of subjects did not complete 24 hours of therapy

subject. Furthermore, a composite made of IL-10, IL-13, and IL- 4 was

because of discontinuations, mostly secondary to clotting. Since anti-

significantly increased at day 17 and day 14, suggesting that there may

coagulation is routinely used in CRRT, Sentien Biotechnologies is now

have been a switch from a Th1 to a Th2 type of response. Finally, a

mandating anticoagulation therapy for all future enrolled subjects.

composite consisting of kidney-related markers such as KIM-1, lipocalin,

At this early stage of development, the primary objective of the

osteoactivin, and uromodulin was found to be statistically significant

study was to assess the safety and tolerability of SBI-101 in patients

between active and sham groups at day 0 up to day 3 and day 7

with AKI-D. With a small sample size, the study was not powered for

(P = .05), suggestive of kidney repair.

clinical efficacy. The small sample size coupled with the complexity

Overall, PD effects as measured by individual molecular and cellular

and seriousness of the patients' current health conditions significantly

biomarkers as well as by composite endpoints were consistent with MSC

contributed to the limitations of this early data set. As this study con-

biology and were indicative of a switch from a pro-inflammatory to an

tinues, efforts (such as requiring anticoagulation therapy for study

anti-inflammatory response that leads to accelerated organ healing and

subjects and potentially harmonizing enrollment based on severity of

repair. These data also supported the hypothesis that ex vivo MSC ther-

disease upon randomization) will be important to evaluate treatment

apy via SBI-101 modulates both adaptive and innate immune cells, as

effect on standard AKI endpoints.

evidenced by changes at the levels of both B and T cells as well as mono-

Pharmacological data were obtained from four treated and four

cytes and dendritic cells. Further studies are needed to increase the sam-

sham subjects, which allowed an initial PK/PD analysis. Results dem-

ple size and investigate the impact of higher doses of MSCs.

onstrated that SBI-101 is active; known MSC-secreted factors were
measured well above sham levels during the 24 hours of treatment.
The secretome measured during treatment was found to have a dif-

4
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DISCUSSION

ferent composition from patient to patient. The differences in composition did not correlate with baseline variability of each product.

AKI-D has a reported mortality rate of 50% to 70%.52,53 Current treat-

Comparison of gene expression profiles of the resulting MSCs with

ments, such as RRT, are supportive and fail to address the underlying

control MSCs prior to treatment would corroborate these secretome
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data. Unfortunately, because of the biohazard nature of the device

on COVID-19 showed that the cytokine storm, and specifically the

after treatment, we were not able to recover the product for post hoc

elevation of TNFα, may inhibit the formation of germinal centers

cellular analysis. These data support a core component of the thera-

resulting in the reduction of the number of memory B cells necessary

peutic hypothesis for SBI-101, namely, that the crosstalk between the

to develop long-term immunity.62 Hence it is plausible that by reduc-

drug substance (MSCs) and the subject's blood cells leads to MSCs

ing TNFα and other Th1 cytokine levels, SBI-101 allows for an

sensing and reacting to their environment55 throughout SBI-101

expanded B-cell response.

treatment. Furthermore, given the close proximity of MSCs to

The immunoprofiling data will be better understood once more

immune cells within the device, short-lived factors such as lipids that

patients are treated. The small number of subjects was a major limita-

cannot diffuse far can still remain bioactive.

tion of the current study and was the motivation for using effect sizes

Unlike the variability observed in the PK response, PD effects

to assess pharmacological changes. Another major limitation was the

were fairly conserved across the treated subjects despite the low

lack of white blood cell counts and differentials for all the patients,

number. The hallmarks of MSC biology were indeed observed in our

which made it difficult to look at the effect of SBI-101 on certain

study, as demonstrated by decreases in TNFα levels and increases in

immune populations, for example, neutrophils. This information will

IL-10 levels.48 The reduction of Th1 cytokines (such as TNFα and

be more efficiently collected going forward, as will other data related

IFNγ) and increase in Th2 cytokines (such as IL-10 and IL-13)

to baseline indicators of severity of disease (eg, sequential organ fail-

suggested a shift from a pro- to an anti-inflammatory state, which was

ure assessment scores) to aid the assessment of clinical outcomes.

also accompanied by the reduction in kidney injury markers such as

Finally, this study has only assessed one dose (250  106 MSCs).

KIM-1. In addition, the composite endpoint made up of TNF family

Higher doses (eg, 500 or 750  106 cells per SBI-101) may enhance

members showed a high effect size. This also supports the potential

the efficacy of SBI-101 and prolong the PD effects relative to those

benefit of SBI-101 on the kidney itself, as the activation of the TNFα

observed in lower doses.

pathway is known to mediate tubular cell injury and contributes

SBI-101 represents a novel ex vivo environment in which human

toward tubular cell loss in AKI.56,57 Of note, elevated PK markers did

MSCs interact in close proximity with the blood system without intro-

not necessarily correspond to an observed pharmacodynamic increase

ducing MSCs directly into a patient. This may be advantageous to mit-

of the same marker, as can be seen by the levels of IL-6 measured in

igate risks of MSC-induced instant blood-mediated inflammatory

SBI-101 and in the patient's plasma after treatment. This speaks to

reactions and other potential safety concerns.63,64 In addition, dosing

the hypothesis underlying the multifaceted approach of MSC therapy,

and fitness of the MSCs can have an impact on potency.47 Hence this

which, in stark contrast to single-agent therapies, targets many biolog-

alternative mode of delivery of MSCs assures a controlled exposure of

ical pathways concomitantly.

blood to a specified number of viable, recovered MSCs over a speci-

Immunomodulation at a molecular level was observed in conjunc-

fied time without administering MSCs directly to a patient, thus pro-

tion with cellular changes. The most striking effect noted was a

viding a longer, directly measurable therapeutic window with an

decrease in monocytes along with a decrease in monocyte and macro-

enhanced safety profile. Because it is designed to address the regula-

phage chemoattractants such as MCP-1 (CCL2), MCP-2 (CCL8), and

tion of programmed transitions in the phenotype of immune effector

MCP-3 (CCL7). Consistent with other clinical reports, these findings

cells as an integrated systems biology problem, SBI-101 is uniquely

have been recently proposed as potential predictive markers of MSC

positioned to serve as an effective therapy to modulate the innate

58

response.

Interestingly, nonclassic monocytes, which are known to

and reprogram the adaptive immune responses. Thus, SBI-101 has

be patrolling, noninflammatory cells, did not decrease with SBI-101

potential for broad applicability to treat diseases with a high unmet

treatment. The reduction of pro-inflammatory monocytes in circula-

medical

tion could be the result of diminished recruitment of monocytes from

inflammation.

need

caused

by

dysregulated,

immune-mediated

the bone marrow or the migration of these cells to the injured tissues.
If these monocytes indeed migrated to the injured tissues, as previously reported when MSCs were administered in a sepsis model,59 it

5
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is plausible that they would differentiate preferentially into M2 macrophages because of the increased levels of TGF-β and Th2 cytokines

We conclude that the ex vivo MSC therapy broadly reprogrammed

also observed in the current study. Unlike the most predominant M1

the molecular and cellular peripheral immune compartment in patients

pro-inflammatory macrophages, M2 macrophages promote healing

with systemic inflammation. Pharmacological data and systems biol-

and tissue regeneration in AKI.60

ogy analysis provided supporting evidence for therapeutic hypothesis,

Although changes in T cells were expected, they did not appear

namely, that treatment with SBI-101 elicits an immunotherapeutic

to be significant or robust at this initial dose level. On the other hand,

response that triggers an accelerated phenotypic switch from tissue

B cells, specifically unswitched memory B cells, did seem to be

injury to tissue repair.

increased with SBI-101 treatment. The effect of MSCs on B cells is
still controversial,61 but the observed result is consistent with in vitro
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